Ana Chumbe

ORCID: 0000-0003-0870-5075
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Monoclonal and Polyclonal Antibodies Research
  • Hepatitis C virus research
  • Virology and Viral Diseases
  • Animal Virus Infections Studies
  • Animal Disease Management and Epidemiology
  • Systemic Lupus Erythematosus Research
  • Hepatitis B Virus Studies
  • SARS-CoV-2 and COVID-19 Research
  • HIV Research and Treatment
  • vaccines and immunoinformatics approaches
  • Vector-Borne Animal Diseases
  • Galectins and Cancer Biology
  • Viral Infections and Vectors
  • Helminth infection and control
  • Microbial infections and disease research
  • Viral Infections and Immunology Research
  • Viral gastroenteritis research and epidemiology
  • Transgenic Plants and Applications
  • Protein purification and stability
  • Plant Pathogenic Bacteria Studies
  • Mollusks and Parasites Studies
  • Invertebrate Taxonomy and Ecology
  • T-cell and Retrovirus Studies
  • Aquaculture disease management and microbiota

University of Amsterdam
2020-2025

University Medical Center
2025

Amsterdam University Medical Centers
2020-2024

Amsterdam University of Applied Sciences
2022

Amsterdam UMC Location University of Amsterdam
2022

National University of San Marcos
2011-2019

Farvet (Peru)
2015-2019

Universidad Peruana Cayetano Heredia
2013

Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma in humans afflicts more than 58 million people worldwide. The HCV envelope E1 E2 glycoproteins are essential for viral entry comprise the primary antigenic target neutralizing antibody responses. molecular mechanisms E1E2 assembly, as well how heterodimer binds broadly antibodies, remain elusive. Here, we present cryo-electron microscopy structure membrane-extracted...

10.1126/science.abn9884 article EN Science 2022-10-20

Hepatitis C virus (HCV) infection affects approximately 58 million people and causes ~300,000 deaths yearly. The only target for HCV neutralizing antibodies is the highly sequence diverse E1E2 glycoprotein. Eliciting broadly that recognize conserved cross-neutralizing epitopes important an effective vaccine. However, most recombinant glycoprotein vaccines, which usually include E2, induce weak antibody responses. Here, we describe soluble immunogens were generated by permutation of E1 E2...

10.1038/s41467-022-34961-8 article EN cc-by Nature Communications 2022-11-25

A vaccine against Hepatitis C virus (HCV) is urgently needed to limit the spread of HCV. The large antigenic diversity HCV glycoprotein E1E2 makes it difficult design a but also fully understand antibody response after infection or vaccination. Here we designed panel pseudoparticles (HCVpps) that cover wide range genetically and antigenically diverse E1E2s. We validate our using neutralization binding multiplex assay (BAMA). HCVpps includes glycoproteins from acute chronically infected cases...

10.1016/j.virusres.2024.199308 article EN cc-by Virus Research 2024-01-11

Hepatitis C virus (HCV) currently causes about one million infections and 240,000 deaths worldwide each year. To reach the goal set by World Health Organization of global HCV elimination 2030, it is critical to develop a prophylactic vaccine. Broadly neutralizing antibodies (bNAbs) target E1E2 envelope glycoproteins on viral surface, can neutralize broad range highly diverse circulating strains, are essential tools inform vaccine design. However, bNAbs targeting single epitope might be...

10.1073/pnas.2420402122 article EN cc-by-nc-nd Proceedings of the National Academy of Sciences 2025-04-07

Great strides have been made in understanding and treating hepatitis C virus (HCV) thanks to the development of various experimental systems including cell-culture-proficient HCV, HCV pseudoparticle system soluble envelope glycoproteins. The (HCVpp) is a platform used extensively studies cell entry, screening novel entry inhibitors, assessing phenotypes clinically observed E1 E2 glycoproteins and, most pertinently, characterizing neutralizing antibody breadth induced upon vaccination natural...

10.1099/jgv.0.001512 article EN Journal of General Virology 2020-11-04

An effective preventive vaccine for hepatitis C virus (HCV) remains a major unmet need. Antigenic region 3 (AR3) on the E1E2 envelope glycoprotein complex overlaps with CD81 receptor binding site and represents an important epitope broadly neutralizing antibodies (bNAbs) is therefore HCV design. Most AR3 bNAbs utilize VH1-69 gene share structural features that define AR3C-class of bNAbs. In this work, we identify recombinant glycoproteins based permuted E2E1 trimer design bind to inferred...

10.1038/s41467-023-39690-0 article EN cc-by Nature Communications 2023-07-07

Newcastle disease is one of the most important infectious diseases poultry, caused by virus (NDV). This distributed worldwide and it can cause severe economic losses in poultry industry due to recurring outbreaks vaccinated unvaccinated flocks. Protection against NDV chickens has been associated with development humoral response. Although hemagglutination inhibition (HI) assay ELISA do not corroborate presence neutralizing antibodies (nAbs); they are used measure protection immune response...

10.1186/s12985-017-0900-8 article EN cc-by Virology Journal 2017-11-23

Although typical Newcastle disease virus (NDV) vaccines can prevent mortality, they are not effective in preventing viral shedding. To overcome this, genotype-matched have been proposed. date, this approach has never tested against genotype XII strains. In study, we generated and assessed the protection challenge of two chimeric NDV vaccine strains (rLS1-XII-1 rLS1-XII-2). The rLS1-XII-1 complete fusion protein (F) hemagglutinin-neuraminidase (HN) open reading frames replaced with those from...

10.1371/journal.pone.0209539 article EN cc-by PLoS ONE 2019-11-14

Infections of poultry with virulent strains avian paramyxovirus 1 (APMV-1), also known as Newcastle disease viruses (NDVs), cause (ND). This highly contagious affects and many other species birds worldwide. In countries where the is prevalent, constant monitoring characterization isolates causing outbreaks are necessary. this study, we report results pathogenicity testing phylogenetic analyses seven NDVs isolated from several regions Peru between 2004 2015. Six had intracerebral indices...

10.1637/11456-062016-reg article EN Avian Diseases 2016-09-27

Avibacterium paragallinarum, the causative agent of infectious coryza, is a highly contagious respiratory acute disease poultry, which affects commercial chickens, laying hens and broilers worldwide.In this study, we performed whole genome sequencing, assembly annotation Peruvian isolate A. paragallinarum. Genome was sequenced in 454 GS FLX Titanium system. De novo completed with Novo Assembler 2.6 using H. influenzae str. F3031 gene model. Manual curation Artemis. Putative function genes...

10.6026/97320630009528 article EN cc-by Bioinformation 2013-06-08

Here, we report the first complete sequence and biological characterization of a Newcastle disease virus (NDV) isolated from peacock in South America (NDV/peacock/Peru/2011). This isolate, classified as genotype XII class II, highlights need for increased surveillance noncommercial avian species.

10.1128/genomea.00792-15 article EN Genome Announcements 2015-07-31

Abstract Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma in humans, afflicts more than 58 million people worldwide. The HCV envelope E1 E2 glycoproteins are essential for viral entry infection, comprise the primary antigenic target neutralizing antibody responses. molecular mechanisms E1E2 assembly, as well how heterodimer binds broadly antibodies, remains elusive. We present cryo-electron microscopy (cryoEM) structure...

10.1101/2021.12.16.472992 preprint EN cc-by bioRxiv (Cold Spring Harbor Laboratory) 2021-12-16

We present here the complete genome sequence of fowl aviadenovirus E (FAdV-E) serotype 8b strain FV211-16, isolated from chickens with inclusion body hepatitis in Peru. Genome comparisons other FAdV-E strains revealed identities 84.9 to 97.1% and presence 9 2 unique amino acid mutations hexon fiber proteins, respectively.

10.1128/genomea.01174-16 article EN Genome Announcements 2016-10-21

The genera Bostryx and Scutalus (Orthalicidae: Bulimulinae) are endemics from South America. They mainly distributed on the western slopes of Peruvian Andes. goal present work was to assess their evolutionary position among stylommatophoran gastropods based 16S rRNA mitochondrial marker. Four sequences were obtained, along with 28 other Stylommatophora retrieved GenBank, aligned ClustalX. phylogenetic reconstruction carried out using methods Neighbor-Joining, Maximum Parsimony, Likelihood...

10.15381/rpb.v16i1.193 article EN cc-by-nc-sa Revista Peruana de Biología 2011-07-06

Great strides have been made in understanding and treating Hepatitis C virus (HCV) thanks part to the development of full-length cell-culture system, pseudoparticle system soluble envelope glycoproteins. The HCV (HCVpp) is a platform used extensively studies cell entry, screening novel entry inhibitors, assessing phenotypes clinically observed E1 E2 glycoproteins and, most pertinently, characterising neutralizing antibody breadth induced upon vaccination natural infection patients....

10.1101/2020.06.18.159442 preprint EN cc-by-nc bioRxiv (Cold Spring Harbor Laboratory) 2020-06-19

A better understanding of the antibody response during natural infection and effect on disease progression reinfection is necessary for development a protective hepatitis C virus (HCV) vaccine. The HCV pseudoparticle (HCVpp) system enables study viral entry inhibition by neutralization. robust comparable neutralization assay crucial evaluation experimental vaccines.With aim optimizing HCVpp-murine leukaemia (MLV) system, we tested HCVpp-harbouring E1E2 from 21 isolates representing 6...

10.1099/jgv.0.001801 article EN Journal of General Virology 2022-11-18

Hepatitis C virus (HCV) currently causes about one million infections and 240,000 deaths worldwide each year. To reach the goal set by World Health Organization (WHO) of global HCV elimination 2030, it is critical to develop a prophylactic vaccine. Broadly neutralizing antibodies (bNAbs) target E1E2 envelope glycoproteins on viral surface, can neutralize broad range highly diverse circulating strains are essential tools inform vaccine design. However, bNAbs targeting single epitope might be...

10.1101/2024.10.04.616615 preprint EN bioRxiv (Cold Spring Harbor Laboratory) 2024-10-04

Abstract An effective preventive vaccine for hepatitis C virus (HCV) remains a major unmet need. Antigenic region 3 (AR3) on the E1E2 envelope glycoprotein complex overlaps with CD81 receptor binding site and represents an important epitope design aimed at inducing broadly neutralizing antibodies (bNAbs). Most AR3 bNAbs utilize V H 1-69 gene share structural features that define AR3C-class of HCV bNAbs. In this work, we identified trimers bind to inferred germline precursors bNAbs, providing...

10.21203/rs.3.rs-2255626/v1 preprint EN cc-by Research Square (Research Square) 2022-11-16

Although typical Newcastle disease virus (NDV) vaccines can prevent mortality, they are not effective preventing viral shedding. To overcome this, genotype-matched have been proposed. date, this approach has never tested against genotype XII strains. In study, we generated and assessed the protection challenge of two chimeric NDV vaccine strains (rLS1-XII-1 rLS1-XII-2). The rLS1-XII-1 complete fusion protein (F) hemmaglutinin-neuraminidase (HN) open reading frames replaced with those from...

10.1101/492421 preprint EN cc-by bioRxiv (Cold Spring Harbor Laboratory) 2018-12-10
Coming Soon ...